Gastrointestinal stromal tumor (GIST) is the most common gastrointestinal mesenchymal tumors

mainly due to the onset of the proto-oncogene receptor tyrosine kinase

or platelet-derived growth factor receptor gene activating mutations. Molecular targeted therapy drug of imatinib mesylate inhibit KIT

platelet-derived growth factor receptor aloha (PDGFRA) gene tyrosine kinase activity

which is effective in patients with advanced GIST. However

a growing number of studies have found the presence of imatinib mesylate in primary and secondary drug resistance in the treatment of GIST process. With the in-depth study of the physiological function and mechanism of action of noncoding RNA in recent years

making it gradually realized extensive regulation of non-coding RNA gene expression

which occurs in tumor development

invasion and metastasis

drug resistance and other processes plays an important role. Non-coding RNA has the potential to explore GIST pathogenesis and resistance mechanisms to provide new ideas and direction.